Breast Cancer Clinical Trial
Official title:
Macrobiotic Diet and Flax Seed: Effects on Estrogens, Phytoestrogens, & Fibrinolytic Factors
This study will assess whether alternative, high phytoestrogen dietary interventions result in favorable effects on biological parameters that have been associated with hormone-dependent cancers, cardiovascular disease, and osteoporosis.
Broad health effects of endogenous and exogenous estrogens on diseases of aging, including
hormone-dependent cancers, cardiovascular disease, and osteoporosis, are generally
recognized. For example, estrogen replacement therapy (ERT) may increase the risk of
subsequent breast and endometrial cancer, but also decreases the risk of coronary disease
and fractures. Because of the increased cancer risk, many women seek out alternatives to
ERT. Phytoestrogens, plant compounds that have estrogenic effects, have been a focus of
interest as an alternative to ERT. The isoflavones and lignans are two major classes of
phytoestrogens that occur in the food supply. Among the former, soy foods have attracted
much interest, while among the latter, whole grains and seeds are sources in a typical diet.
More specifically, women consuming a macrobiotic diet have been observed to have extremely
high levels of phytoestrogen metabolites in their urine, perhaps 10 to 20 times that seen in
women consuming an omnivorous diet. Proponents of a macrobiotic diet have proposed that it
is beneficial in the context of cancer therapy, as well as for the prevention and treatment
of cardiovascular disease.
This study will investigate, in a randomized, three-arm study, the effects of two
interventions that are high in phytoestrogens on various parameters related to estrogen
metabolism and fibrinolysis. Approximately 120 women will be randomized to receive an
American Heart Association (AHA) Step 1 diet, an AHA Step 2 diet + 10 g/day flax seed, or a
macrobiotic dietary intervention. Blood and urine samples will be drawn at baseline, and at
three, six, nine, and twelve months, to examine both short and long-term effects of these
interventions. Outcomes include blood and urine levels of total estrogens and estradiol, and
related metabolites; antigens to plasminogen activator inhibitor-1 (PAI-1) and tissue
plasminogen activator (t-PA), fibrin D-dimer, and von Willebrand Factor; and endothelial
function as measured by high-resolution ultrasound. Blood levels of antioxidant vitamins and
retinoids will also be examined.
This study should provide information on whether these alternative, high phytoestrogen
dietary interventions result in favorable effects on these biological parameters that are
related to risk of major diseases of aging.
;
Allocation: Randomized, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
| Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
| Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
| Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
| Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
| Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
| Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
| Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
| Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
| Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
| Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
| Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
| Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
| Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
| Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
| Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
| Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
| Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
| Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 |